Antibiotics: first case of penicillin-resistant group B streptococcus reported in Italia
Focus on responsible use: in 2025, the rates of resistance to the main classes of antibiotics for the eight pathogens under surveillance remain high and, in some cases, are on the rise
A strain of Streptococcus agalactiae (Group B Streptococcus, or GBS) resistant to penicillin – the first-line antibiotic used both for the treatment of invasive infections and for intrapartum antibiotic prophylaxis – has been identified in Italia for the first time this year. This has been reported by the Italian National Institute of Health ahead of European Antibiotic Awareness Day on 18 November. The occasion also serves as a reminder that ‘rates of antibiotic resistance in Italia generally remain high, although there are signs of improvement’.
The case
In 2024, the WHO had, for the first time, classified penicillin-resistant Group B Streptococcus as a medium-priority pathogen, highlighting how the loss of efficacy of beta-lactam antibiotics against this microorganism represents an emerging threat to global public health, with a particular impact on the most vulnerable groups and on neonatal health.
The bacterium was isolated in February 2026 from a blood culture taken from an adult patient by the Piacenza Local Health Authority (AUSL), which sent the isolate to the Italian National Institute of Health (ISS) for confirmation of resistance and molecular characterisation. Laboratory analyses and genomic sequencing confirmed that the strain (serotype Ia, Sequence Type 23) had an MIC value of 0.25 mg/L, linked to previously known and ‘de novo’ identified point mutations in the penicillin-binding protein genes pbp2a and pbp2x, and was found to be resistant to other antibiotics, such as levofloxacin, erythromycin and tetracycline.
This first national isolation case, published in *Eurosurveillance*, “means we must remain vigilant across the country to safeguard the effectiveness of prevention and treatment protocols”, the Institute explains.
Data for Italy
Antibiotic resistance rates in Italy generally remain high, although there are signs of improvement. The use of hydroalcoholic hand sanitiser in hospitals has also risen slightly, whilst still falling far short of the rates recommended by the WHO. ‘Combating antibiotic resistance to preserve the effectiveness of antibiotics in treating infections and their consequences for health and healthcare systems. This is the key message of the event that we wish to share with all stakeholders,’ says Anna Teresa Palamara, head of the Department of Infectious Diseases at the ISS. - Combating resistance requires a range of integrated measures, including surveillance, research, health policies, and the development of new diagnostic, preventive and therapeutic strategies. This is a complex problem that calls for long-term collaborative efforts, which our system is called upon to address.”

